Prostate cancer is a common malignant tumor of the genitourinary system in elderly men and has become a major health hazard for men. The European Association of Urology (EAU) survey study shows that as of 2012, prostate cancer has become the most common solid tumor in Europe, with an incidence rate of more than 21.4%, higher than lung cancer and colon cancer, and its mortality rate has become the second highest cancer mortality rate in men. In China, the incidence and mortality rate of prostate cancer are on the rise. Epidemiological surveys have found that between 2003 and 2007, the incidence and mortality rate of prostate cancer increased by 59.32% and 58.03%, respectively, and has become the 3rd most common malignant tumor in the urological system, becoming the most common malignant tumor in elderly men. Prostate cancer can cause symptoms similar to lower urinary tract obstruction or irritation, and in severe cases, acute urinary retention, hematuria and urinary incontinence may occur. Bone metastasis can cause bone pain, pathological fracture, anemia, spinal cord compression leading to lower limb paralysis, etc. The long-term existence of these clinical symptoms seriously affects patients’ quality of life. Prostate cancer is prone to distant metastasis, which makes the disease difficult to cure and eventually makes patients face the threat of death. With the aging of our population, the danger of prostate cancer to men is increasing and should be taken seriously, but the initial symptoms of the disease are not obvious and are often easily ignored.